

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

NCT07255846

Status	RECRUITING
Phase	Phase 1
Sponsor	Terremoto Biosciences Inc.
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (8)

- Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
- A clinical diagnosis of HHT as defined by the Curaçao criteria
- Baseline (1-month) ESS e 4
- ECOG d 2
- Anemia or parental iron infusion of at least 500 mg or transfusion of at least 2 units of RBCs within the preceding 24 weeks.
- ... and 3 more (see full listing online)

Exclusion (4)

- Prior nonresponse or loss of response to an agent that inhibits AKT1 and/or AKT2 as the primary mechanism of action.
- Diagnosis of DM requiring insulin treatment
- Known significant bleeding sources other than nasal, GI, or menstrual/ uterine
- Known underlying hypoproliferative anemia or clinically significant hemolytic anemia

Locations (1 total)

Innovative Hematology, Inc., Indianapolis, Indiana, United States